| 主权项 |
1. A method of treating neutrophil infiltration, hemorrhagic shock or lung inflammation in an individual comprising administering to the individual an effective amount of a compound having the structure of Formula I: or a pharmaceutically acceptable salt thereof, wherein: L1 is selected from the group consisting of —C—C—C—; —O—C—C—; —O—C—C—C—; or the bridge structure shown below each optionally substituted with one or more R1A; L2 is aryl or heteroaryl each optionally substituted with one or more with one or more R2A; each R1A is independently selected from the group consisting of hydroxy, halo, cyano, nitro, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkenyl, (cyclolalkyl)alkyl, (R1BBR1CCN)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro,
said aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkenyl, and (cyclolalkyl)alkyl in the definition of R1A are each optionally substituted with one or more R1AA; each R1AA is independently selected from the group consisting of hydroxy, halo, cyano, nitro, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkenyl, (cyclolalkyl)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro; each R2A is independently selected from the group consisting of hydroxy, halo, cyano, nitro, —S(O)zNR1BR1C, —NHS(O)zNR1BR1C, —OC(═O)NR1BR1C, —NHC(═O)NR1BR1C, —C(═O)NR1BR1C, —NR1BR1C, —S(O)zR1D, —NHS(O)zR1D, —NHC(═O)R1D, —OC(═O)R1D, —C(═O)R1D, —C(═O)OR1D, hydroxy(C1-C6)alkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, (cyclolalkyl)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro; R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, hydroxy, halo, cyano, nitro, —S(O)zNR1BR1C, —NHS(O)zNR1BR1C, —OC(═O)NR1BR1C, —NHC(═O)NR1BR1C, —C(═O)NR1BR1C, —NR1BR1C, —S(O)zR1D, —NHS(O)zR1D, —NHC(═O)R1D, —OC(═O)R1D, —C(═O)R1D, —C(═O)OR1D, hydroxy(C1-C6)alkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, (cyclolalkyl)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro; each NR1BR1C is independently selected, wherein R1B and R1C are each independently from the group consisting of hydrogen, C1-6alkyl, aryl, arylalkyl, cycloalkyl, (cyclolalkyl)alkyl, (R1BBR1CCN)alkyl, and (R1BBR1CCN)C(═O)—; each R1D is independently selected from the group consisting of hydroxy, aryl, heteroaryl, heterocyclyl, arylalkyl, cycloalkyl, cycloalkenyl, (cyclolalkyl)alkyl, (R1BBR1CCN)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro; each R1BBR1CCN is independently selected, wherein R1BB and R1CC are each independently from the group consisting of hydrogen, C1-6alkylOC(═O)—, C1-6alkyl, C1-6alkylC(═O)—, aryl, arylalkyl, cycloalkyl, and heterocyclyl; X is N (nitrogen) or NR11; each z is independently 0, 1 or 2; R11 is H (hydrogen) or C1-6 alkyl; X2 is C (carbon), or CR12; R12 is H (hydrogen) or C1-6 alkyl; and each dashed line is an optional double bond. |
